Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J CONDUCTING CLINICALS FOR MERIDIAN UTEST FOR OTC USE

This article was originally published in The Gray Sheet

Executive Summary

J&J CONDUCTING CLINICALS FOR MERIDIAN UTI TEST FOR OTC USE under the terms of a licensing pact between Johnson & Johnson's Advanced Care Products and Meridian Diagnostics. On April 7, Meridian announced that it has granted Advanced Care exclusive worldwide marketing rights to its FiltraCheck urinary tract infection test for the over-the-counter market. Currently, there are no UTI tests cleared for OTC marketing. Meridian sells FiltraCheck to hospitals, commercial labs and physicians' offices under 510(k) clearance from FDA. According to Meridian, "at least 60 million urinary screening tests are performed annually in the U.S. in hospitals, physicians' offices and nursing homes." After gathering clinical data, Advanced Care will submit a marketing application to FDA for the home-use indication. Meridian says that it is not clear whether FDA will require a 510(k) or a premarket approval application. Another recently cleared OTC test -- the ChemTrak/American Home Products CholesTrac cholesterol test -- was okayed for marketing under a 510(k) ("The Gray Sheet" March 8, p. 14). In Advanced Care, Meridian has an experienced marketing partner for the OTC diagnostics market. The J&J division sells the Advance and Fact Plus home pregnancy test lines. The licensing pact calls for Meridian to manufacture the OTC test and sell it directly to Advanced Care at a set price. The tests, which will be shipped in bulk by Meridian, will be packaged by Advanced Care. J&J has not yet determined whether it will market the tests in packages of one, two or three single-use tests, according to Meridian. FiltraCheck is a colorimetric test that screens urine for the presence of bacteria and white blood cells, which indicate the presence of pyuria. Four drops of urine are placed in a well in the center of the hand-held device. After 20 seconds, a reagent is added, and the test is read after an additional 30 seconds. If there is a color change, the test is positive; if there is no change, it is negative ("The Gray Sheet" July 22, 1991, p. 5). Meridian says that only packaging modifications are necessary to adapt the test for consumer use.

You may also be interested in...



Novartis Logs Into India With Digital Innovation Hub

Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.

Rx List Price Inflation Penalty Endorsed By US HHS Secretary

Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.

Generics Approvals Will Decline, US FDA Predicts, But Supplement Work May Grow

With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.

UsernamePublicRestriction

Register

MT000474

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel